Google is testing a new lectures Audio Overview style in NotebookLM that can turn notes into a single-host, 30-minute explanation. The Lecture format would sit alongside existing modes, such as Deep ...

EXCLUSIVE: More leaked PowerPoint lectures from a first-year University of Illinois Urbana-Champaign class show left-wing ideology woven into the fabric of the course. Fox News Digital obtained course ...

This is read by an automated voice. Please report any issues or inconsistencies here. Hungarian Nobel Prize laureate László Krasznahorkai delivered a rare lecture in Stockholm, presenting ...

Lectures on Tap series brings professors and other experts into Boston restaurants and bars for talks that mix big ideas with food and drink. Lectures on Tap, an event series, brings ticketed lectures ...

Who is the Antichrist, the biblical antagonist whose rise marks the beginning of the end-times? Peter Thiel recently took a stab at answering this age-old question. Thiel kicks off the lecture series ...

SEATTLE — A psychology lecture at the University of Washington erupted into turmoil on Wednesday when a man barged into one of the campus’s largest classrooms, raising a Nazi salute and shouting ...

AbbVie will pay up to US$1.2 billion to acquire Gilgamesh’s short-acting psychedelic bretisilocin, highlighting growing industry interest in hallucinogenic drugs for the treatment of psychiatric ...

Gilgamesh Brewing started in 2009 by three brothers and their father in Turner. They opened their first restaurant and pub in 2012 in southeast Salem. From 2019 to 2024, they opened three more ...

AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead pipeline asset bretisilocin, a clinical-stage candidate designed to treat moderate-to-severe major depressive disorder (MDD), for up to ...

Aug 25 - AbbVie (ABBV.N), opens new tab will buy an experimental depression drug from partner Gilgamesh Pharmaceuticals for up to $1.2 billion, the companies said on Monday, seeking to access a ...

AbbVie (NYSE:ABBV) has agreed to acquire from Gilgamesh Pharmaceuticals its lead investigational candidate, Bretisilocin, for up to $1.2 billion. The deal includes upfront payment plus development ...

Gilgamesh's lead asset, bretisilocin (GM-2505), is a potential best-in-class psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD). Bretisilocin is ...